linjc16/ctgov huggingface dataset:
Risk Factors of POCD in General Anesthesia Patients Underwent Noncardiac and Non Neurological Procedures.

Study Overview
=================
Brief Summary
-----------------
The study was a prospective cohort study to assess the effect of age, duration of anesthesia, repeated surgery, and type of surgery on cognitive impairment in 108 geriatric patients (≥60 years) who underwent general anesthesia for non-neurologic noncardiac surgery.

Detailed Description
-----------------
The study was a prospective cohort study, assessing the effect of age, duration of anesthesia, repeated surgery, and type of surgery on cognitive impairment in 108 geriatric patients (≥60 years) who underwent general anesthesia for non-neurologic noncardiac surgery. The study used cognitive tests such as RAVLT, TMT, and Digit span tests. POCD definition is reduction in postoperative cognitive function by as much as 20% at a minimum of 2 cognitive tests.

Official Title
-----------------
Risk Factors of Post Operative Cognitive Dysfunction (POCD) in General Anesthesia Patients Underwent Noncardiac and Non Neurological Procedures.

Conditions
-----------------
Undergoing General Anaesthesia

Intervention / Treatment
-----------------
* Other: Questionaire


Participation Criteria
=================
Eligibility Criteria
-----------------
Inclusion Criteria: geriatric patient (age over 60) underwent noncardiac non-neurological procedure under general anesthesia patient can do reading and writing patient can speak in Bahasa signing informed consent Exclusion Criteria: patient with cognitive impairment or psychiatric disorder such as delirium, amnesia, anxiety disorder, or depression. patient under psychotropic drugs or narcotics. patient with history of brain tumor, head injury or motoric disturbance and disability that can disturbed neurocognitive test

Ages Eligible for Study
-----------------
Minimum Age: 60 Years

Sexes Eligible for Study
-----------------
All

Accepts Healthy Volunteers
-----------------
No

Study Plan
=================
How is the study designed?
-----------------

Arms and Interventions

| Participant Group/Arm | Intervention/Treatment |
| --- | --- |
| Geriatric patient underwent general anesthesia procedure<br>geriatric patients (≥60 years) ware assessed for cognitive impairment after general anesthesia for non-neurologic noncardiac surgery. | Other: Questionaire<br>* Patient was assessed using mini international neuropsychiatric interview<br>|

What is the study measuring?
-----------------
Primary Outcome Measures

| Outcome Measure | Measure Description | Time Frame |
| --- | --- | --- |
| Mini International Neuropsychiatric Interview | Score was assessed using 6 forms | 7 days | 

 Terms related to the study
=================
Keywords Provided by Centre Hospitalier Valida
-----------------
postoperative cognitive dysfunction, geriatrics, general anaesthesia
Phase II Study of the Effect of Leuprolide Acetate and Spironolactone on Insulin Resistance in Hyperandrogenic Women With Polycystic Ovarian Disease or Hyperandrogenism Insulin Resistance Acanthosis Nigricans Syndrome

Study Overview
=================
Brief Summary
-----------------
OBJECTIVES: I. Evaluate insulin resistance in thin and obese hyperandrogenic women with polycystic ovarian disease or hyperandrogenism insulin resistance acanthosis nigricans syndrome and in thin and obese controls, using an estimation of tissue sensitivity to insulin. II. Evaluate the effect of androgen suppression with leuprolide acetate and spironolactone on insulin secretion and resistance.

Detailed Description
-----------------
PROTOCOL OUTLINE: Participants are treated with subcutaneous leuprolide acetate followed by oral spironolactone. Each treatment is administered daily for 6 weeks, with a 6-week washout between drugs. Patients and controls are alternately assigned to begin treatment with leuprolide acetate or spironolactone.

Conditions
-----------------
Acanthosis Nigricans, Polycystic Ovary Syndrome

Intervention / Treatment
-----------------
* Drug: leuprolide acetate
* Drug: spironolactone


Participation Criteria
=================
Eligibility Criteria
-----------------
PROTOCOL ENTRY CRITERIA: --Disease Characteristics-- Polycystic ovarian disease Oligomenorrhea or amenorrhea Hirsutism Hyperandrogenism Hyperandrogenism insulin resistance acanthosis nigricans syndrome Hyperandrogenism Oligomenorrhea or amenorrhea Insulin resistance Acanthosis nigricans Hematocrit at least 30% Women with normal menstrual cycles not using oral contraception entered as controls

Ages Eligible for Study
-----------------
Minimum Age: 0 Years

Sexes Eligible for Study
-----------------
Female

Accepts Healthy Volunteers
-----------------
No

Study Plan
=================
How is the study designed?
-----------------

Design Details

Primary Purpose: Treatment


Arms and Interventions

| Intervention/Treatment |
| --- |
|Drug: leuprolide acetate|nan|
|Drug: spironolactone|nan|

What is the study measuring?
-----------------
Primary Outcome Measures

| Outcome Measure | Measure Description | Time Frame |
| --- | --- | --- |

 Terms related to the study
=================
Keywords Provided by Centre Hospitalier Valida
-----------------
acanthosis nigricans, dermatologic disorders, endocrine disorders, polycystic ovarian syndrome, rare disease
Impact Of RA Therapy Compliance On Patient-Reported Outcomes

Study Overview
=================
Brief Summary
-----------------
Several observational studies have evaluated the comparative treatment costs associated with each agent, particularly those within the anti-TNF class, but few have evaluated the impact of therapy compliance, persistence, treatment patterns on patient reported outcomes, healthcare utilization and costs, using a provider database. This study is designed to fill in this information gap.

Detailed Description
-----------------
Cohort observational

Official Title
-----------------
Impact Of RA Therapy Compliance On Patient-Reported Outcomes

Conditions
-----------------
Rheumatoid Arthritis

Intervention / Treatment
-----------------
* Drug: tDMARDs
* Drug: biodmards


Participation Criteria
=================
Eligibility Criteria
-----------------
Inclusion Criteria: Adults with moderate to severe RA who are currently using a DMARD Exclusion Criteria: Psoriatic Arthritis (PsA), Psoriasis (PsO), SSystemic Lupus Erythematosus (SLE), Non-Disease modifying anti-rheumatic disease (non-DMARD) use

Ages Eligible for Study
-----------------
Minimum Age: 18 Years

Sexes Eligible for Study
-----------------
All

Accepts Healthy Volunteers
-----------------
No

Study Plan
=================
How is the study designed?
-----------------

Arms and Interventions

| Participant Group/Arm | Intervention/Treatment |
| --- | --- |
| tDMARDs Group<br>traditional DMARDs | Drug: tDMARDs<br>* Traditional DMARDs for RA<br>|
| Biologics group<br>Biologics used in RA | Drug: biodmards<br>* Biologic DMARDs<br>|

What is the study measuring?
-----------------
Primary Outcome Measures

| Outcome Measure | Measure Description | Time Frame |
| --- | --- | --- |
| HAQ |  | 12 months | 
| 36-Item Short-Form Health Survey (SF-36) |  | 12 months | 

Secondary Outcome Measures

| Outcome Measure | Measure Description | Time Frame |
| --- | --- | --- |
| Compliance |  | 12 months | 

 Terms related to the study
=================
Keywords Provided by Centre Hospitalier Valida
-----------------
rheumatoid arthritis, therapy compliance
Oral Health-related Quality of Life (OHRQoL) in Patients With Inflammatory Bowel Disease (IBD)

Study Overview
=================
Brief Summary
-----------------
IBD patients have a higher risk of oral diseases that affect the oral mucosa, the teeth and the tooth supporting tissues. These conditions are often associated with pain, bleeding and impaired masticatory function which may have an impact on the oral health-related quality of life (OHRQoL). However, few studies have investigated the self-evaluation of oral quality of life in IBD patients. The rare existing studies focus on very specific patients (elderly patients, patients with stomas) and do not use validated tools for the evaluation of OHRQoL. We also lack data on the effect of treatments such as immunosuppressants and type of IBD on OHRQoL. The aim of this study is to (i) compare oral quality of life in a cohort of IBD patients versus non-IBD patients and (ii) explore potential factors that influence oral quality of life in IBD

Official Title
-----------------
Self-rated Oral Health and Factors Associated With Oral Health-related Quality of Life (OHRQoL) in Patients With Inflammatory Bowel Disease (IBD)

Conditions
-----------------
Inflammatory Bowel Diseases, Periodontitis, Dental Caries, Tooth Loss

Intervention / Treatment
-----------------
* Other: Self-administrated questionnaires


Participation Criteria
=================
Eligibility Criteria
-----------------
Inclusion Criteria: Adults ≥ 18 years of age With Crohn's disease or ulcerative colitis Able to understand and answer the questions asked Exclusion Criteria: Unable to understand and/or answer questions Not willing to participate in the study

Ages Eligible for Study
-----------------
Minimum Age: 18 Years

Sexes Eligible for Study
-----------------
All

Accepts Healthy Volunteers
-----------------
No

Study Plan
=================
How is the study designed?
-----------------

Arms and Interventions

| Participant Group/Arm | Intervention/Treatment |
| --- | --- |
| IBD patients<br> | Other: Self-administrated questionnaires<br>* GOHAI, IBD-Q, IBD-disk<br>|
| Non-IBD patients (irritable bowel syndrome)<br> | Other: Self-administrated questionnaires<br>* GOHAI, IBD-Q, IBD-disk<br>|

What is the study measuring?
-----------------
Primary Outcome Measures

| Outcome Measure | Measure Description | Time Frame |
| --- | --- | --- |
| GOHAI score |  | Baseline (One time only on the day of the consultation ) | 

 Terms related to the study
=================
Keywords Provided by Centre Hospitalier Valida
-----------------
Crohn disease, Ulcerative Colitis, oral diseases, Oral health-related quality of life, self-questionnaire
3D Ultrasound Measurement of Junctional Zone Thickness and Its Relation to Implantation Success

Study Overview
=================
Brief Summary
-----------------
100 patients aged 21-40 years old, diagnosed as primary or secondary infertility . These patients are then assigned to receive fertility treatment (ovulation induction, ICSI, intrauterine insemination and IVF). They undergo a 3D vaginal ultrasound before treatment to measure the junctional zone thickness and followed up after treatment to determine the rate of implantation.

Official Title
-----------------
Thickness of the Junctional Zone Measured by 3D Ultrasound and Its Relation to the Success/Failure Implantation Rates in Assisted Reproduction Techniques

Conditions
-----------------
Infertility

Intervention / Treatment
-----------------
* Radiation: 3D ultrasound


Participation Criteria
=================
Eligibility Criteria
-----------------
Inclusion Criteria: infertile women Exclusion Criteria: congenital uterine anomalies medical disease contraindicating pregnancy

Ages Eligible for Study
-----------------
Minimum Age: 21 Years
Maximum Age: 40 Years

Sexes Eligible for Study
-----------------
Female

Accepts Healthy Volunteers
-----------------
No

Study Plan
=================
How is the study designed?
-----------------

Arms and Interventions

| Participant Group/Arm | Intervention/Treatment |
| --- | --- |
| pregnant<br>These patients are then assigned to receive fertility treatment (ovulation induction, ICSI, intrauterine insemination and IVF). They undergo a 3D vaginal ultrasound before treatment to measure the junctional zone thickness and followed up after treatment to determine the rate of implantation and they became pregnant | Radiation: 3D ultrasound<br>* ultrasound to measure the thickness of the junctional zone at day 21 of the cycle<br>|
| Non pregnant<br>These patients are then assigned to receive fertility treatment (ovulation induction, ICSI, intrauterine insemination and IVF). They undergo a 3D vaginal ultrasound before treatment to measure the junctional zone thickness and followed up after treatment to determine the rate of implantation and they remained non pregnant | Radiation: 3D ultrasound<br>* ultrasound to measure the thickness of the junctional zone at day 21 of the cycle<br>|

What is the study measuring?
-----------------
Primary Outcome Measures

| Outcome Measure | Measure Description | Time Frame |
| --- | --- | --- |
| pregnancy rate |  | 14 days after evaluation | 

Secondary Outcome Measures

| Outcome Measure | Measure Description | Time Frame |
| --- | --- | --- |
| healthy pregnancy |  | 6 weeks after pregnancy confirmation by pregnancy test | 

 Terms related to the study
=================
Keywords Provided by Centre Hospitalier Valida
-----------------
junctional zone, implantation, three D ultraosund, Assisted Reproductive Technology, Pregnancy
Comparison Efficacy of 14-day Triple Therapy: Clarithromycin vs. Levofloxacin on Eradication of H. Pylori

Study Overview
=================
Brief Summary
-----------------
Comparison Efficacy of 14-day Triple Therapy between Clarithromycin and levofloxacin on the Eradication of Helicobacter Pylori in Syrian population

Official Title
-----------------
Comparison Efficacy of 14-day Triple Therapy Between Clarithromycin and Levofloxacin on the Eradication of Helicobacter Pylori in Syrian Population

Conditions
-----------------
Helicobacter Pylori Gastrointestinal Tract Infection

Intervention / Treatment
-----------------
* Drug: Clarithromycin
* Drug: Levofloxacin


Participation Criteria
=================
Eligibility Criteria
-----------------
Inclusion Criteria: 1-Patients are aged greater than 18 years old who have H. pylori infection diagnosed by any of following three methods: I-Positive rapid urease test (CLOtest). II-Histologic evidence of H. pylori by modified Giemsa staining. III-Positive 13C-urea breath test. without prior eradication therapy and are willing to receive therapy. Exclusion Criteria: Children and teenagers aged less than 18 years. Previous eradication treatment for H. pylori. Patients who took any drug, which could influence the study results such as proton pump inhibitor, H2 blocker, mucosal protective agent and antibiotics. History of gastrectomy. Gastric malignancy, including adenocarcinoma and lymphoma, Previous allergic reaction to antibiotics (Amoxicillin, Clarithromycin, Levofloxacin) and prompt pump inhibitors (Es-omeprazole). Contraindication to treatment drugs. Pregnant or lactating women. Severe concurrent disease. Liver cirrhosis. Chronic kidney disease. Patients who cannot give informed consent by himself or herself.

Ages Eligible for Study
-----------------
Minimum Age: 18 Years
Maximum Age: 75 Years

Sexes Eligible for Study
-----------------
All

Accepts Healthy Volunteers
-----------------
No

Study Plan
=================
How is the study designed?
-----------------

Design Details

Primary Purpose: Treatment
Allocation: Randomized
Intervention Model: Parallel Assignment
Masking: Single


Arms and Interventions

| Participant Group/Arm | Intervention/Treatment |
| --- | --- |
| Active Comparator: Clarithromycin<br>Clarithromycin 500 mg Tablets and Esomeprazole 20 mg Capsule And Amoxicillin 1000 mg,Tablets by mouth every 12 hours for 14 days | Drug: Clarithromycin<br> <br> * Other names: Amoxicillin;|
| Experimental: Levofloxacin<br>Levofloxacin 500 mg coated tablets and Esomeprazole 20 mg Capsule and Amoxicillin 1000 mg Tablets by mouth every 12 hours for 14 days | Drug: Levofloxacin<br> <br> * Other names: Amoxicillin;|

What is the study measuring?
-----------------
Primary Outcome Measures

| Outcome Measure | Measure Description | Time Frame |
| --- | --- | --- |
| Eradication rate according to Intention to treat (ITT) and per-protocol (PP) analysis |  | 6 weeks after eradication therapy | 

 Terms related to the study
=================
Keywords Provided by Centre Hospitalier Valida
-----------------
Helicobacter pylori, Helicobacter Infections, Proton Pump Inhibitors
A Retrospective, Blinded Validation of a Host-response Based Diagnostics

Study Overview
=================
Brief Summary
-----------------
This is a retrospective, blinded, external validation study of a novel in-vitro diagnostic (IVD) assay that will include samples that were previously collected from febrile pediatric patients. The investigated assay measures the levels of a few host-related, blood-based, bio-markers that will be integrated into a single score. Based on this score, each patient will be classified into one of three categories: (i) bacterial immune response, (ii) viral immune response, and (iii) marginal immune response. The assay prediction and the patient diagnosis will than be unveiled and compared to determine their level of concordance.

Official Title
-----------------
A Retrospective, Blinded Validation Study to Assess the Accuracy of a Host-response Based Diagnostics for Distinguishing Between Bacterial and Viral Etiologies in Pediatric Patients With an Acute Febrile Disease

Conditions
-----------------
Fever, Respiratory Tract Infections, Urinary Tract Infections, Gastroenteritis, Arthritis, Infectious

Participation Criteria
=================
Eligibility Criteria
-----------------
Inclusion Criteria: The infectious disease samples should also fulfill the following criteria: The patient had a peak temperature ≥38°C (AND) Symptoms initiated ≤ 7 days before sampling The non-infectious disease control group will include: Patients with a non-infectious disease Exclusion Criteria: Another infection episode during the last 3 weeks before sampling Congenital immune deficiency (CID) A proven or suspected HIV-1, HBV, HCV infection Active hematological malignancy Current treatment with immune-suppressive or immune-modulating Other illnesses that affect life expectancy and/or quality of life

Ages Eligible for Study
-----------------
Minimum Age: 1 Month
Maximum Age: 18 Years

Sexes Eligible for Study
-----------------
All

Accepts Healthy Volunteers
-----------------
No

Study Plan
=================
How is the study designed?
-----------------
What is the study measuring?
-----------------
Primary Outcome Measures

| Outcome Measure | Measure Description | Time Frame |
| --- | --- | --- |
| The sensitivity and specificity of the assay in differentiating between bacterial and viral etiology of patients with an acute febrile disease | We will evaluate the assay using the accuracy measures sensitivity and specificity of differentiating between bacterial and viral etiology of pediatric patients aged 1 month to 18 years with an acute febrile disease. | 0-7 days after the initiation of symptoms | 

Secondary Outcome Measures

| Outcome Measure | Measure Description | Time Frame |
| --- | --- | --- |
| The sensitivity and specificity of the assay in differentiating between infectious and non-infectious disease etiology. | We will evaluate the assay using the accuracy measures sensitivity and specificity of differentiating between infectious and non-infectious disease etiology in pediatric patients aged 1 month to 18 years. | 0-7 days after the initiation of symptoms |
Phase 2 Study of ALN-RSV01 in Lung Transplant Patients Infected With Respiratory Syncytial Virus (RSV)

Study Overview
=================
Brief Summary
-----------------
To evaluate the safety,tolerability and antiviral activitity of ALN-RSV01 in RSV infected lung transplant patients

Official Title
-----------------
A Multi-Center, Randomized, Double-blind, Placebo-Controlled Study to Evaluate the Safety and Antiviral Activity of Aerosolized ALN-RSV01 Plus Standard of Care in Lung Transplant Patients Infected With Respiratory Syncytial Virus (RSV)

Conditions
-----------------
Respiratory Syncytial Virus Infections

Intervention / Treatment
-----------------
* Drug: ALN-RSV01
* Drug: normal saline


Participation Criteria
=================
Eligibility Criteria
-----------------
Inclusion Criteria: Single or bilateral lung transplant recipients Confirmed RSV infection Greater than 90 days post current lung transplant Rejection free for a minimum of 1 month Exclusion Criteria: Antimicrobial therapy for known viral, bacterial, or fungal respiratory co-infection at the time of diagnosis Bronchiolitis obliterans syndrome (BOS) Grade 3 or any state BOS with FEV1 that has not been stable for at least 3 months Use of alemtuzumab within 9 months prior to screening; anti-thymocyte globulin(ATG) or thymoglobulin within 3 months of screening: concurrent use of >= 0.3 mg/kg/day prednisone or equivalent as maintenance therapy active treament for acute graft rejection

Ages Eligible for Study
-----------------
Minimum Age: 18 Years

Sexes Eligible for Study
-----------------
All

Accepts Healthy Volunteers
-----------------
No

Study Plan
=================
How is the study designed?
-----------------

Design Details

Primary Purpose: Treatment
Allocation: Randomized
Intervention Model: Parallel Assignment
Masking: Quadruple


Arms and Interventions

| Participant Group/Arm | Intervention/Treatment |
| --- | --- |
| Active Comparator: 1<br>ALN-RSV01 | Drug: ALN-RSV01<br>* administered by nebulization once daily for 3 days<br>|
| Placebo Comparator: 2<br>Normal saline | Drug: normal saline<br>* administered by nebulization once daily for 3 days<br>|

What is the study measuring?
-----------------
Primary Outcome Measures

| Outcome Measure | Measure Description | Time Frame |
| --- | --- | --- |
| Assess safety and tolerability of aerosolized ALN-RSV01 versus placebo in lung transplant patients infected with RSV |  | Day 30 | 

Secondary Outcome Measures

| Outcome Measure | Measure Description | Time Frame |
| --- | --- | --- |
| Evaluate effects of ALN-RSV01 on clinical and virologic endpoints |  | Throughout Trial | 

 Terms related to the study
=================
Keywords Provided by Centre Hospitalier Valida
-----------------
ALN-RSV01, Respiratory Syncytial Virus
Aortic Stiffness in Chronic Kidney Disease Stage 2 to 4

Study Overview
=================
Brief Summary
-----------------
This study aimed to investigate in a cohort with chronic kidney disease the longitudinal relationship between aortic stiffness and renal function and mortality.

Official Title
-----------------
Evaluation of Aortic Stiffness in CKD II to IV

Conditions
-----------------
Decline in Renal Function

Participation Criteria
=================
Eligibility Criteria
-----------------
Inclusion Criteria: Age 18 or older CKD 2-4 Exclusion Criteria: pregnancy history of malignant disease with a prognostic life expectancy less than 24 months missing of written and informed consent

Ages Eligible for Study
-----------------
Minimum Age: 18 Years

Sexes Eligible for Study
-----------------
All

Accepts Healthy Volunteers
-----------------
No

Study Plan
=================
How is the study designed?
-----------------

Arms and Interventions

| Participant Group/Arm | Intervention/Treatment |
| --- | --- |
| CKD Cohort of patients with renal insufficiency<br>patients with renal insufficiency grade II-IV | |

What is the study measuring?
-----------------
Primary Outcome Measures

| Outcome Measure | Measure Description | Time Frame |
| --- | --- | --- |
| combined renal end-point (>25% decline in renal function or start of renal replacement therapy) |  | 24 months | 

Secondary Outcome Measures

| Outcome Measure | Measure Description | Time Frame |
| --- | --- | --- |
| mortality |  | 24 months | 

 Terms related to the study
=================
Keywords Provided by Centre Hospitalier Valida
-----------------
chronic kidney disease, CKD, pulse wave velocity, PWV